NCT05515185 is a EARLY_PHASE1 clinical trial of KT095 CAR-T injection in Advanced Solid Tumor, sponsored by The First People's Hospital of Lianyungang.

Who is sponsoring NCT05515185?

NCT05515185 is sponsored by The First People's Hospital of Lianyungang.

What drugs are being tested in NCT05515185?

Interventions in NCT05515185: KT095 CAR-T injection.

What condition does NCT05515185 study?

NCT05515185 studies Advanced Solid Tumor.

Is NCT05515185 still recruiting?

NCT05515185 is currently status unknown. Last updated 25 August 2022.

Last reviewed 2022-08-25 · How we verify

NCT05515185

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors

Status unknown EARLY_PHASE1 Last updated 25 August 2022

What this trial tests

EARLY_PHASE1 trial testing KT095 CAR-T injection in Advanced Solid Tumor in 30 participants. Status unknown.

Timeline

9 September 2022

Primary endpoint
8 September 2024

8 September 2024

Quick facts

Lead sponsor	The First People's Hospital of Lianyungang
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	9 September 2022
Primary completion	8 September 2024
Estimated completion	8 September 2024
Sites	1 location across China

Drugs / interventions tested

KT095 CAR-T injection — full drug profile →

Conditions studied

Advanced Solid Tumor — all drugs for Advanced Solid Tumor →

Sponsor

The First People's Hospital of Lianyungang

Who can join

Adults 18 to 70, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a clinical study to evaluate the safety and efficacy of CAR-T cells in the treatment of patients with advanced solid tumors in China.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment.
Yan T, Zhu L, Chen J. · · 2023 · cited 132× · PMID 36707873 · DOI 10.1186/s40164-023-00373-7
B7-H3 Inhibitors in Oncology Clinical Trials: A Review.
Feustel K, Martin J, Falchook GS. · · 2024 · cited 45× · PMID 38327753 · DOI 10.36401/jipo-23-18
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors.
Khan SH, Choi Y, Veena M, Lee JK, et al · · 2024 · cited 27× · PMID 39835140 · DOI 10.3389/fimmu.2024.1489827
Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications.
Guo Y, Wang X, Zhang C, Chen W, et al · · 2025 · cited 16× · PMID 40171330 · DOI 10.2147/itt.s507522
CAR Based Immunotherapy of Solid Tumours-A Clinically Based Review of Target Antigens.
Maher J, Davies DM. · · 2023 · cited 13× · PMID 36829563 · DOI 10.3390/biology12020287
Non-immune functions of B7-H3: bridging tumor cells and the tumor vasculature.
Wu S, Hu C, Hui K, Jiang X. · · 2024 · cited 12× · PMID 38952550 · DOI 10.3389/fonc.2024.1408051
Revolutionizing cancer treatment: the emerging potential and potential challenges of <i>in vivo</i> self-processed CAR cell therapy.
Lv R, Guo Y, Liu W, Dong G, et al · · 2024 · cited 6× · PMID 39659573 · DOI 10.7150/thno.101941
B7-H3 in Cancer Immunotherapy-Prospects and Challenges: A Review of the Literature.
Mielcarska S, Kot A, Dawidowicz M, Kula A, et al · · 2025 · cited 5× · PMID 40801642 · DOI 10.3390/cells14151209

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumor

Currently open trials in the same condition.

NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting

Other The First People's Hospital of Lianyungang trials

Trials by the same sponsor.

NCT07481006 — Association Between Intraoperative Mean Arterial Pressure Variability and Postoperative Fatigue in Patients Undergoing L · not yet recruiting
NCT07323043 — Comparison of Cough Response Between Tegilidine and Sufentanil as Pre-induction Agents in General Anesthesia · NA · recruiting
NCT07279051 — Modified Mini-Open TLIF vs Traditional Open TLIF · NA · not yet recruiting
NCT07096115 — ED90 of Teglidine for Suppressing LMA Insertion Response in the Elderly · NA · not yet recruiting
NCT07081477 — Ciprofol's Influence on LVOT VTI in Elderly Painless Colonoscopy Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05515185 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First People's Hospital of Lianyungang
Last refreshed: 25 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05515185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing